New Leaf closes $200M growth equity fund

New Leaf Venture Partners closed a $200 million growth equity fund that will focus solely on investments in later-stage public biopharma companies. The firm's Philippe Chambon told BioCentury that New Leaf Growth Fund I is "meant to be a very flexible vehicle to invest in what we consider the most interesting companies from a return perspective over a long period of time."

New Leaf considers later-stage to be a "question of risk profile and market cap" and not necessarily a distinction between precommercial and commercial-stage companies, according to Chambon. ...